Ischemia Modified Albumin (IMA) - A Marker of Glycaemic Control and Vascular Complications in Type 2 Diabetes Mellitus

Chawla, Rajinder; Loomba, Rinchu; Guru, Deepak; Loomba, Vikas

doi:10.7860/jcdr/2016/15282.7432

Cited by 17 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positive association of IMA with a glycemic index (FPG and A1C) authenticates that hyperglycemia provokes hypoxia, oxidative stress, and ischemia leading vascular complications in type 2 diabetes [13,22,39]. The present study attempted to find out the relationship of IMA with lipid status in DN.…”

Section: Correlation Of Ima With Lipid Statusmentioning

confidence: 87%

“…Aetiopathogenesis of DN is connected with the generation of free radicals or reactive oxygen species (ROS) which causes hypoxia, ischemia and vascular inflammatory changes [12]. Oxidative damage and sub-endothelial inflammation due to hyperglycemia, hyperlipidemia and high blood pressure lead to conformational changes of different biomolecules also in N-terminal of albumin causing formation of IMA [13][14][15]. Blood IMA levels increases due to hyperglycemia, hyperlipidemia, and inflammation resulting in reduce metal binding capacity of albumin to bind cobalt [16].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Association between Ischemia Modified Albumin (IMA), Glycemic and Lipid Status in Diabetic Nephropathy

Ahmad¹,

Manjrekar

Agarwal³

et al. 2019

IJBcRR

View full text Add to dashboard Cite

Introduction: Hyperglycemia induced oxidative stress in Type 2 Diabetes Mellitus modify various biomolecules to cause Diabetic Nephropathy (DN). IMA (Ischemia-Modified Albumin) is one such oxidative stress marker already examined in various clinical events but have not yet been evaluated in different stages of DN. Aim: To estimate and assess the relationship of IMA with glycemic status and lipid parameters in all stages of DN. Study Design: Cross-sectional study. Place and Duration of Study: Study was conducted at Department of Biochemistry, Kasturba Medical College Hospitals, Mangaluru conducted between 2014 and 2015. Materials and Methods: There were 60 type 2 diabetic cases and 30 healthy controls. Diabetic cases were further categorized into three equal groups on the basis of UACR (urine albumin-creatinine ratio), DN stage I having UACR less than 30 mg/g, DN stage II having UACR 30 to 300 mg/g, and DN stage III having UACR ≥ 300 mg/g of creatinine. Using enzyme-linked immunosorbent assay serum IMA level was estimated whereas automated analyzers was used for serum creatinine, HbA1c, urine albumin and urine creatinine analysis. Results: Lowest level of IMA (109 ng/mL) measured in DN stage I, which was significantly different from those in DN stage II (154 ng/mL) and DN stage III (178 ng/mL). The significant positive correlation between IMA and fasting blood glucose, glycated hemoglobin were present in stage II and stage III DN. In this study significant positive correlation of serum IMA to serum total cholesterol, low density lipoprotein cholesterol and negative correlation with high density lipoprotein were revealed in all stage of DN. Conclusion: Current study postulates that early evaluation of serum IMA in diabetic patients with deranged lipid profile will provide an index of nephropathy development. This will help in prognosis and controlling complication in diabetes mellitus.

show abstract

Section: Correlation Of Ima With Lipid Statusmentioning

confidence: 87%

Section: Introductionmentioning

confidence: 99%

Evaluation of the Association between Ischemia Modified Albumin (IMA), Glycemic and Lipid Status in Diabetic Nephropathy

Ahmad¹,

Manjrekar

Agarwal³

et al. 2019

IJBcRR

View full text Add to dashboard Cite

show abstract

“…We discovered a significant increase in serum IMA concentration in the subjects with aMCI compared with the cognitively normal controls. Additionally, serum IMA concentration might be affected by many factors, such as chronic diseases, life history, and medications . Therefore, a multivariate analysis was performed, and all the potential confounding factors were well adjusted.…”

Section: Discussionmentioning

confidence: 99%

Serum ischaemia‐modified albumin might be a potential biomarker for oxidative stress in amnestic mild cognitive impairment

et al. 2018

Psychogeriatrics

View full text Add to dashboard Cite

Background: Amnestic mild cognitive impairment (aMCI) is considered to be a prodromal stage of Alzheimer's disease. The clinical role of ischaemiamodified albumin (IMA) and the association between IMA and oxidative stress in aMCI have not been investigated. The aim of the study was to explore this relationship and to generate new ideas for controlling Alzheimer's disease. Methods: This community-based case-control study included 113 patients with aMCI and 832 cognitively normal controls. Serum levels of albumin and IMA, diacron-reactive oxygen metabolite, and biological anti-oxidant potential, were measured. The IMA/albumin ratio and the biological antioxidant potential/diacron-reactive oxygen metabolite ratio were calculated. Results: In univariate analysis, the serum IMA level and the IMA/albumin ratio were higher in the aMCI patients than in the controls (P < 0.001, P < 0.001, respectively). In multivariate analysis, a serum IMA level ≥476.4 ng/mL and an IMA/albumin ratio ≥9.4 were separately associated with the development of aMCI (odds ratio = 3.56, 95% confidence interval: 2.33-5.46; odds ratio = 3.43, 95% confidence interval: 2.25-5.27, respectively). There was a linear correlation between serum IMA level and several oxidative stress markers (biological anti-oxidant potential/diacron-reactive oxygen metabolite ratio: r = −0.585, P < 0.001; diacron-reactive oxygen metabolite: r = 0.549, P < 0.001; biological anti-oxidant potential: r = −0.293, P < 0.001). Conclusion: Serum IMA might be a potential biomarker for oxidative stress in aMCI.

show abstract

“…High levels of ischemia modified albumin (IMA) clearly predicted bumin was found in different conditions while evaluating for ischemic heart disease including cholecystitis, pericarditis, pancreatitis, stroke, seizures and pulmonary thromboembolic phenomena. 20,21,22,23,24,25,26 Ischemia modified albumin may thus be used as a surrogate marker in those conditions but more prospective detailed studies are required in the future. It can be utilized as a rule out test rather than rule in test due to high negative predictive value along with electrocardiogram (EKG) and troponin (cTnT) to increase sensitivity and specificity.…”

Section: Discussionmentioning

confidence: 99%

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Nepal¹,

Jaisawal²,

Guragain³

et al. 2017

JCDR

View full text Add to dashboard Cite

Aims and Objectives: To find out if ischemia modified albumin can be a novel marker in ischemic heart disease. Materials and methods: Retrospective chart-review of chest pain patients who were evaluated in the emergency departments in 2006 and 2007. Results: Total of 400 patients presented with chest pain and subsequently were evaluated in the Emergency department at two major emergency departments associated with the teaching hospital associated Mercy Catholic Medical Center; few patients were excluded due to unavailability of complete data and follow-up visit in next six months. Thus, finally 351 patients met criteria for final analysis. Primary endpoints included the cardiac events and secondary outcomes were course in the hospital, days of hospitalization, interventions done in the hospital, disposition from the hospital, and readmission within next six months. Sensitivity and specificity of ischemia modified albumin (IMA) test was 80% and 50% respectively and positive predictive value and negative predictive values were 17% and 88% respectively. There were no further differences in cardiac events or interventions in higher ischemia modified albumin (IMA) group as compared to troponin (cTnT) (p=0.5). People with higher ischemia modified albumin (IMA) showed longer hospitalization days (p=0.025), needing nursing home or skilled nursing facility on discharge due to high discharge needs (p=0.0001) and had more readmissions as compared to troponin (p=0.02). However, Higher ischemia modified albumin (IMA) did not predict more cardiovascular events during hospital stay, rather troponin (cTnT) test predicted arrhythmia more than ischemia modified albumin (IMA) test (p=0.0001). Conclusion: Ischemia-modified albumin may be utilized as a novel marker of ischemia to rule out acute coronary syndrome along with troponin and electrocardiogram in the emergency departments. This test may also have short and long-term prognostic significances and may even be used as a surrogate marker in stroke, sepsis and thrombo-embolic diseases once these people need admission to the hospital.

show abstract

Ischemia Modified Albumin (IMA) - A Marker of Glycaemic Control and Vascular Complications in Type 2 Diabetes Mellitus

Cited by 17 publications

References 14 publications

Evaluation of the Association between Ischemia Modified Albumin (IMA), Glycemic and Lipid Status in Diabetic Nephropathy

Evaluation of the Association between Ischemia Modified Albumin (IMA), Glycemic and Lipid Status in Diabetic Nephropathy

Serum ischaemia‐modified albumin might be a potential biomarker for oxidative stress in amnestic mild cognitive impairment

Ischemic Modified Albumin (IMA) as a Novel Marker for Ischemic Heart Disease and Surrogate Marker for Other High Oxidative -Ischemic Conditions

Contact Info

Product

Resources

About